Newsletter | November 27, 2019

11.27.19 -- WHO Elaborates Upon Biosimilar Prequalification Progress

Featured Editorial
WHO Elaborates Upon Biosimilar Prequalification Progress
By Anna Rose Welch, editor, Biosimilar Development

One technical expert from WHO outlined the current requirements for the two pathways for biosimilar prequalification and the progresses and pitfalls for companies seeking a spot on the WHO’s list of prequalified medicines.

Will Authorized Biologics Disrupt The Market For Biosimilars?
By Ha Kung Wong and Erica L. Norey, Venable Fitzpatrick

Many of the doomsday scenario predictions for biosimilar competition if authorized biologics were to enter the space prematurely assume mainstream development and adoption of authorized biologics by innovator companies in the current market and do not take into consideration the outcomes seen over the past 18 years with authorized small molecule generics.

Drug Coupons: An Ongoing Debate Between States, Payers, And Manufacturers
By Stephanie Hoops, Decision Resources Group

The clock is ticking for state lawmakers to preserve an existing law that allows for prescription drug coupon usage in Massachusetts with an end-of-the-year deadline fast approaching.

Industry Insights
Optimizing Drug Safety And Efficacy Of Complex Next-Generation Biologics
White Paper | GE Healthcare Life Sciences

Learn about the challenges that exist in developing biologic drugs and how novel analytical techniques, such as surface plasmon resonance, can help circumvent these issues and optimize development.

Standing Out In The Crowded Biopharma CDMO Market
Webinar | ISR Reports

When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection they are able to communicate what is unique about their offerings to the right audience at the right time. 

Purification Platform For IgMs
Bio-Rad Laboratories, Inc.
Connect With Biosimilar Development: